Plain-English translation of NCT06950697 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Researchers are studying how often blood clots develop in lung cancer patients receiving immune checkpoint inhibitors—a type of cancer treatment that helps the body's immune system fight cancer. The goal is to identify warning signs and create a simple risk prediction tool that doctors can use to prevent blood clots or catch them early in patients taking this medication.
Blood clots are a serious side effect that can happen in some lung cancer patients on immune-boosting treatments, but doctors don't yet have a reliable way to predict who will develop them. This study aims to fill that gap by identifying the specific risk factors and biomarkers that make certain patients more vulnerable, so doctors can provide better prevention and monitoring.
You likely qualify if…
You likely don't qualify if…
As a participant, you would allow researchers to review your medical records and track your health over time while you receive your lung cancer treatment. The study will collect information about your background, your treatment, any blood clots that develop, and blood samples or other biomarkers—but you won't need to take any new medication or make extra hospital visits beyond your regular cancer care appointments.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China